KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Shares Issued (2016 - 2025)

Nektar Therapeutics has reported Shares Issued over the past 16 years, most recently at -$456000.0 for Q4 2025.

  • Quarterly results put Shares Issued at -$456000.0 for Q4 2025, down 101.52% from a year ago — trailing twelve months through Dec 2025 was $34.1 million (up 13.54% YoY), and the annual figure for FY2024 was $30.0 million, changed.
  • Shares Issued for Q4 2025 was -$456000.0 at Nektar Therapeutics, down from $34.3 million in the prior quarter.
  • Over the last five years, Shares Issued for NKTR hit a ceiling of $34.3 million in Q3 2025 and a floor of -$30.0 million in Q2 2024.
  • Median Shares Issued over the past 5 years was $342500.0 (2022), compared with a mean of $6.1 million.
  • Biggest five-year swings in Shares Issued: plummeted 166644.44% in 2024 and later surged 263746.15% in 2025.
  • Nektar Therapeutics' Shares Issued stood at $1.8 million in 2021, then crashed by 94.28% to $103000.0 in 2022, then plummeted by 117.48% to -$18000.0 in 2023, then soared by 166572.22% to $30.0 million in 2024, then tumbled by 101.52% to -$456000.0 in 2025.
  • The last three reported values for Shares Issued were -$456000.0 (Q4 2025), $34.3 million (Q3 2025), and $218000.0 (Q2 2025) per Business Quant data.